CX 2024 Programme
Day 1: Peripheral Arterial Controversies - Tuesday, 23rd April
Venue: Theatre 1
Time: 08:00 - 18:00
Paclitaxel Mortality Controversy
Time: 08:00 - 08:45
| Anchor: | Andrew Holden, Auckland, New Zealand |
| Moderators: | Sahil Parikh, New York, United States |
| Marianne Brodmann, Graz, Austria | |
| Barry Katzen, Miami, United States |
08:00 - 08:05
Audience participation, discussion & voting
08:05 - 08:10
Update on the safety of paclitaxel-coated balloons for femoropopliteal occlusive disease
| Speaker: | Thomas Zeller, Bad Krozingen, Germany |
08:10 - 08:15
Paclitaxel and mortality
| Speaker: | Peter Schneider, San Francisco, United States |
08:15 - 08:20
Late Breaker: Did the meta-analysis and regulatory body restrictions on paclitaxel cause harm
| Speaker: | Eric Secemsky, Boston, United States |
Final Perspective from Regulatory Authorities
Time: 08:20 - 08:30
08:20 - 08:25
FDA response
| Speaker: | Ariel Ash-Shakoor, Washingston, United States |
08:25 - 08:30
MHRA response
| Speaker: | Alexander McLaren, London, United Kingdom |
08:30 - 08:45
Audience participation, discussion & voting
| Faculty: | Sahil Parikh, New York, United States |
| William Gray, Wynnewood, United States |
Drug-Coated Balloons in the Femoropopliteal Arteries
Time: 08:45 - 10:10
| Anchor: | Thomas Zeller, Bad Krozingen, Germany |
| Moderators: | Robert Hinchliffe, Bristol, United Kingdom |
| Robert Morgan, London, United Kingdom |
08:45 - 08:50
Audience participation, discussion & voting
08:50 - 08:55
Paclitaxel and sirolimus-coated balloons in the femoropopliteal arteries: Mechanisms of action
| Speaker: | Bruno Scheller, Hamburg, Germany |
08:55 - 09:00
Long-term success with a market leading paclitaxel DCB: The IN.PACT RCT and Global Registry
| Speaker: | Gunnar Tepe, Rosenheim, Germany |
09:00 - 09:05
Three-year outcomes after paclitaxel-coated balloon angioplasty of femoropopliteal arteries among patients in the French National Health Data System
| Speaker: | Yann Goueffic, Paris, France |
09:05 - 09:20
Audience participation & discussion
09:20 - 09:25
Sirolimus trials in the SFA: SFA IDE and SUCCESS PTA trials
| Speaker: | Michael Lichtenberg, Arnsberg, Germany |
09:25 - 09:30
Sirolimus trials in the SFA, including the FUTURE SFA Asia RCT
| Speaker: | Edward Choke, Bukit Merah, Singapore |
09:30 - 09:35
Sirolimus vs paclitaxel, a head to head trial: Update of the SIRONA RCT
| Speaker: | Ulf Teichgraeber, Jena, Germany |
09:35 - 09:50
Audience participation & discussion
09:50 - 10:00
Debate: After the FDA announcement, paclitaxel-coated devices now beat limus-coated devices
For the motion
09:50 - 09:55
| Andrew Holden, Auckland, New Zealand |
Against the motion
09:55 - 10:00
| Marianne Brodmann, Graz, Austria |
10:00 - 10:10
Audience participation, discussion & voting
Coffee break
Time: 10:10 - 10:30
Bioresorbable Scaffolds in Tibial Arteries
Time: 10:30 - 11:20
| Anchor: | Gunnar Tepe, Rosenheim, Germany |
| Moderators: | Sahil Parikh, New York, United States |
| Jos van den Berg, Lugano, Switzerland |
10:30 - 10:35
Bioresorbable scaffolds in tibial arteries: The holy grail
| Speaker: | Ramon Varcoe, Sydney, Australia |
10:35 - 10:40
Late Breaker: Latest data release from the LIFE-BTK clinical trial
| Speaker: | Brian DeRubertis, New York, United States |
10:40 - 10:45
Current expectations of a CLTI clinical trial: A regulatory body perspective
| Speaker: | Ariel Ash-Shakoor, Washingston, United States |
10:45 - 10:55
Audience participation & discussion
10:55 - 11:00
Update on a sirolimus-eluting PLLA scaffold in tibial arteries
| Speaker: | Eric Secemsky, Boston, United States |
11:00 - 11:05
Update on a bioresorbable scaffold in tibial arteries
| Speaker: | Michel Bosiers, Bern, Switzerland |
11:05 - 11:10
The multi-element balloon expandable bioresorbable vascular scaffold system in the SFA
| Speaker: | Andrew Holden, Auckland, New Zealand |
11:10 - 11:20
Audience participation & discussion
Vessel Preparation in Tibial Artery Occlusive Disease
Time: 11:20 - 12:30
| Anchor: | Brian DeRubertis, New York, United States |
| Moderators: | Gunnar Tepe, Rosenheim, Germany |
| Lindsay Machan, Vancouver, Canada |
11:20 - 11:25
What are the concepts behind vessel preparation devices?
| Speaker: | Brian DeRubertis, New York, United States |
11:25 - 11:30
What is the evidence for vessel preparation with atherectomy in BTK arteries?
| Speaker: | Thomas Zeller, Bad Krozingen, Germany |
11:30 - 11:35
Clinical outcomes for below-the-ankle intervention in CLI: A Liberty 360 study sub-analysis
| Speaker: | George Adams, Chapel Hill, United States |
11:35 - 11:45
Audience participation & discussion
11:45 - 11:50
Intravascular lithotripsy in BTK arteries: Data and new technologies
| Speaker: | Andrew Holden, Auckland, New Zealand |
11:50 - 11:55
Edited Case: Treatment of tibial lesions with a new laser-based IVL technology
| Speaker: | Marianne Brodmann, Graz, Austria |
11:55 - 12:05
Audience participation & discussion
12:05 - 12:10
An update on the DEEPER trials with a novel retrievable temporary stent system
| Speaker: | Marianne Brodmann, Graz, Austria |
12:10 - 12:15
CHOCO-CABANA trial: A prospective, randomised trial comparing a specialty balloon system versus conventional PTA in BTK arteries
| Speaker: | Gunnar Tepe, Rosenheim, Germany |
12:15 - 12:20
Are vessel preparation devices cost-effective?
| Speaker: | Jos van den Berg, Lugano, Switzerland |
12:20 - 12:30
Audience participation & discussion
Sponsored education
Time: 12:30 - 13:00
Advancements in lower limb PAD revascularisation: Role and value of sirolimus-eluting balloons
Time: 12:30 - 13:00
| Moderator: | George Adams, Chapel Hill, United States |
| Faculty: | Athanasios Diamantopoulos, London, United Kingdom |
| Bruno Migliara, Peschiera del Garda, Italy |
12:30 - 12:32
Introduction
| Speaker: | George Adams, Chapel Hill, United States |
12:32 - 12:47
SELUTION SLR™ Sirolimus DEB in PAD
| Speaker: | Athanasios Diamantopoulos, London, United Kingdom |
12:47 - 12:57
Sirolimus eluting balloon in SFA/POP
| Speaker: | Bruno Migliara, Peschiera del Garda, Italy |
12:57 - 13:00
Conclusion
| Speaker: | George Adams, Chapel Hill, United States |
Lunch break
Time: 13:00 - 13:30
Inaugural Roger M Greenhalgh Late Breaking Trials Session
Time: 13:30 - 15:20
Deep Venous Arterialisation
Time: 13:30 - 14:35
| Anchor: | Robert Hinchliffe, Bristol, United Kingdom |
| Moderators: | Thomas Zeller, Bad Krozingen, Germany |
| Andrew Holden, Auckland, New Zealand |
13:30 - 13:35
Audience participation, discussion & voting
13:35 - 13:40
Transcatheter arterialisation of the deep veins: Highlights of the PROMISE trials
| Speaker: | Daniel Clair, Nashville, United States |
13:40 - 13:45
Late Breaker: New data from the CLARITY trial
| Speaker: | Anahita Dua, Boston, United States |
13:45 - 13:50
Late Breaker: Final results from the PROMISE UK trial
| Speaker: | Hany Zayed, London, United Kingdom |
13:50 - 14:00
Audience participation & discussion
14:00 - 14:05
The PiPeR DVA technique
| Speaker: | Bruno Migliara, Peschiera del Garda, Italy |
14:05 - 14:10
New considerations in DVA
| Speaker: | Steven Kum, Singapore, Singapore |
14:10 - 14:15
Post DVA management
| Speaker: | Uei Pua, Singapore, Singapore |
14:15 - 14:25
Audience participation & discussion
14:25 - 14:30
Deep venous arterialisation: A word of caution
| Speaker: | Thomas Zeller, Bad Krozingen, Germany |
14:30 - 14:35
Audience participation, discussion & voting
Aorto-iliac Occlusive Disease
Time: 14:35 - 15:20
| Anchor: | Robert Morgan, London, United Kingdom |
| Moderators: | Brian DeRubertis, New York, United States |
| Thomas Zeller, Bad Krozingen, Germany |
14:35 - 14:40
A new classification for aorto-iliac occlusive disease
| Speaker: | Ross Milner, Chicago, United States |
14:40 - 14:45
Results from the DISCOVER RCT
| Speaker: | Bram Fioole, Rotterdam, Netherlands |
14:45 - 14:50
An update of the FORWARD clinical study comparing uncovered to covered stents in the iliac arteries
| Speaker: | Andrew Holden, Auckland, New Zealand |
14:50 - 15:00
Audience participation & discussion
15:00 - 15:05
Expanding options to tackle iliac calcification with intravascular lithotripsy
| Speaker: | Stefano Fazzini, Rome, Italy |
15:05 - 15:10
Latest data on covered endovascular repair of the aortic bifurcation
| Speaker: | Maria Antonella Ruffino, Lugano, Switzerland |
15:10 - 15:20
Audience participation & discussion
Sponsored Education
Time: 15:20 - 15:50
Tea break
Time: 15:50 - 16:10
BASIL-3 Podium First Presentation
Time: 16:10 - 18:00
| Anchor: | Andrew Holden, Auckland, New Zealand |
| Moderators: | Dittmar Boeckler, Heidelberg, Germany |
| Robert Hinchliffe, Bristol, United Kingdom |
16:10 - 16:15
Introduction to BASIL-3
| Speaker: | Andrew Bradbury, Birmingham, United Kingdom |
16:15 - 16:20
Evidence for paclitaxel DCB/DES in CLTI before BASIL-3
| Speaker: | Lewis Meecham, Cardiff, Wales |
16:20 - 16:25
BASIL-3 in context: BASIL Prospective Cohort Study (PCS)
| Speaker: | Matthew Popplewell, Birmingham, United Kingdom |
16:25 - 16:30
BASIL-3 methodology: Clinical
| Speaker: | Gareth Bate, Birmingham, United Kingdom |
16:30 - 16:35
BASIL-3 methodology: Statistical
| Speaker: | Jack Hall, Birmingham, United Kingdom |
16:35 - 16:40
BASIL-3 clinical results
| Speaker: | Catherine Moakes, Birmingham, United Kingdom |
16:40 - 16:45
BASIL-3 health economic results
| Speaker: | Jesse Kigozi, Birmingham, United Kingdom |
16:45 - 16:50
Summing up, limitations, take home messages, and further research
| Speaker: | Andrew Bradbury, Birmingham, United Kingdom |
16:50 - 17:30
Audience participation & roundtable discussion
17:30 - 17:50
Great Debate: Bypass surgery is better than endovascular surgery
For the motion
17:30 - 17:35
| Matthew Menard, Boston, United States |
17:40 - 17:45
| Michael Conte, San Francisco, United States |
Against the motion
17:35 - 17:40
| Andrew Bradbury, Birmingham, United Kingdom |
17:45 - 17:50
| Ramon Varcoe, Sydney, Australia |
17:50 - 18:00
Audience participation, discussion & voting